title: An FDA review of sulfamethazine toxicity.
abstract: Recently, changes have been proposed in the criteria historically used in the evaluation of the applicability to humans of some of the results obtained from the rodent carcinogenicity bioassay data. These questions center on the suitability of the rodent model for agents that exert their toxic effects via specific enzyme interactions and endocrine mechanisms which appear to be inoperative within humans. Within the U.S. Food and Drug Administration (FDA), this issue has been brought to the forefront of concern with the recent application for a New Animal Drug Application for sulfamethazine (SMZ). A panel of FDA experts from the National Center for Toxicological Research (NCTR), the Center for Veterinary Medicine (CVM), and the Center for Food Safety and Applied Nutrition has reviewed the sum of the scientific evidence available on the toxicology of SMZ. They noted that, in previous feeding studies at NCTR, high doses of SMZ were associated with significant incidences of thyroid tumors in mice and rats. The panel also notes that the tumorigenic activity of SMZ in rodents was due to its goitrogenic activity, resulting in constant stimulation of the thyroid by TSH. Humans, on the other hand, were found to be insensitive to the SMZ-like inhibition of thyroid function. Further, apart from X-irradiation and radioactive iodine, there are no other physical or chemical agents known to cause thyroid tumors in humans. Thus, the expert panel concludes that the best scientific information available indicates that elevated levels of TSH and the consequent thyroid tumors would not be produced under approved use conditions of SMZ. This conclusion is in agreement with recommendations made by three other panels, viz. the World Health Organization, the U.S. Environmental Protection Agency, and CVM, which also evaluated the public health risk of SMZ.
authors.affiliation: Division of Molecular Epidemiology, NCTR, Jefferson, Arkansas, 72079, USA.
authors.forename: L A
authors.initials: LA
authors.lastname: Poirier
authors.forename: D R
authors.initials: DR
authors.lastname: Doerge
authors.forename: D W
authors.initials: DW
authors.lastname: Gaylor
authors.forename: M A
authors.initials: MA
authors.lastname: Miller
authors.forename: R J
authors.initials: RJ
authors.lastname: Lorentzen
authors.forename: D A
authors.initials: DA
authors.lastname: Casciano
authors.forename: F F
authors.initials: FF
authors.lastname: Kadlubar
authors.forename: B A
authors.initials: BA
authors.lastname: Schwetz
mesh_terms: D000818:Animals; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000633:toxicity*; D015197:Carcinogenicity Tests / Q000379:methods; D002273:Carcinogens / Q000009:adverse effects / Q000633:toxicity*; D006801:Humans; D013418:Sulfamethazine / Q000009:adverse effects / Q000633:toxicity*; D013964:Thyroid Neoplasms / Q000139:chemically induced; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000890:Anti-Infective Agents; D002273:Carcinogens; D013418:Sulfamethazine